title: Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies.
abstract: OBJECTIVE
  To determine the efficacy and toxicity of etoposide, cyclophosphamide, and fractionated total-body irradiation (TBI) as the conditioning regimen for allogeneic bone marrow transplantation (BMT) in patients with hematologic malignancies.
  
  
  METHODS
  Seventy-nine patients underwent BMT from a human leukocyte antigen (HLA)-identical sibling using cyclosporine/methotrexate for graft-versus-host disease (GVHD) prophylaxis. Thirty-four patients had early leukemia (acute leukemia or lymphoblastic lymphoma in first remission, chronic myelogenous leukemia [CML], or refractory anemia [RA]), and 45 patients had more advanced disease. Patients received etoposide 1,500 mg/m2 on day -8, followed by cyclophosphamide 60 mg/kg/d on days -7 and -6, and 10.2 Gy of TBI administered in six fractions of 1.7 Gy given twice daily for 3 days from day -3 to -1. Donor bone marrow was harvested and infused on day 0.
  
  
  RESULTS
  Patients with early leukemia had a disease-free survival rate of 53% +/- 9% and an overall survival rate of 57% +/- 10% at 3 years. Patients with advanced disease had a disease-free survival rate of 15% +/- 5% and overall survival rate of 17% +/- 5%. The actuarial relapse rate for the early-leukemia group is 33% +/- 9% versus 69% +/- 9% for patients with more advanced disease. Severe toxicity was most frequently manifested as pulmonary hemorrhage followed by multiorgan failure and death. The 100-day mortality rate for the early-leukemia group was 10% versus 50% for patients with more advanced disease.
  
  
  CONCLUSIONS
  The combination of cyclophosphamide, etoposide, and TBI is a relatively safe and effective preparative regimen for patients with early hematologic malignancies. Controlled trials are needed to evaluate critically this combination versus other standard preparative regimens. Greater toxicity was observed in patients with advanced disease, and this program does not appear to offer any advantage over other regimens.
authors.affiliation: Department of Hematology, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
authors.forename: S A
authors.initials: SA
authors.lastname: Giralt
authors.forename: C F
authors.initials: CF
authors.lastname: LeMaistre
authors.forename: H M
authors.initials: HM
authors.lastname: Vriesendorp
authors.forename: B S
authors.initials: BS
authors.lastname: Andersson
authors.forename: M
authors.initials: M
authors.lastname: Dimopoulos
authors.forename: J
authors.initials: J
authors.lastname: Gajewski
authors.forename: K
authors.initials: K
authors.lastname: Van Besien
authors.forename: R
authors.initials: R
authors.lastname: Mehra
authors.forename: D
authors.initials: D
authors.lastname: Przepiorka
authors.forename: I
authors.initials: I
authors.lastname: Khouri
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007938:Leukemia / Q000401:mortality / Q000628:therapy*; D008171:Lung Diseases / Q000209:etiology; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D015996:Survival Rate; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation / Q000009:adverse effects
chemical_list: D005047:Etoposide; D003520:Cyclophosphamide